Companies Dominating the Respiratory Disorders Treatment Landscape
- Mylan N.V.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva PharmaceuticalIndustries Ltd.
- Sunovion Pharmaceuticals Inc.
- Merck & Co., Inc.
- BoehringerIngelheim Pharmaceuticals, Inc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Regeneron Pharmaceuticals, Inc.
- Grifols, S.A.
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of respiratory disorders treatment is assessed at USD 121.16 billion.
Respiratory Disorders Treatment Market size was valued at USD 115.09 billion in 2024 and is expected to reach USD 251.57 billion by 2037, registering around 6.2% CAGR during the forecast period i.e., between 2025-2037.
North America industry is anticipated to hold largest revenue share by 2037, led by increased awareness among the people about the respiratory diseases and the supporting government policies.
The major players in the market are Mylan N.V., Teva PharmaceuticalIndustries Ltd., Sunovion Pharmaceuticals Inc., Merck & Co., Inc., BoehringerIngelheim Pharmaceuticals, Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Regeneron Pharmaceuticals, Inc., Grifols, S.A., Pfizer Inc., and others.
